A Minimal Genome Simian Foamy Virus Type 1 Vector System with Efficient Gene Transfer  by Park, Jeonghae et al.
Virology 302, 236–244 (2002)A Minimal Genome Simian Foamy Virus Type 1 Vector System with Efficient Gene Transfer
Jeonghae Park, Peter E. Nadeau, and Ayalew Mergia1
Department of Pathobiology, University of Florida, Gainesville, Florida 32610
Received June 24, 2002; returned to author for revision June 11, 2002; accepted June 20, 2002
Foamy viruses have several inherent features for the opportunity to develop efficient and versatile vectors for gene
therapy. We have constructed a series of vectors and helper plasmids based on simian foamy virus type 1 (SFV-1) to establish
the minimum vector genome required for efficient gene transduction. To characterize the efficiency of gene transduction by
these vectors, the green fluorescent protein (GFP) coding sequence is linked to the human cytomegalovirus immediate gene
promoter. Several deletion analyses of SFV-1 vectors revealed that the minimum genome with efficient GFP transduction
contained the 5 untranslated region extending to the first 637 nucleotides of the gag gene, a 596 nucleotides of pol sequence
from position 3137–3733, the 3 pol region at position 5200–5693, the 3 end polypurine tract, and the 3 LTR. An additional
1131 nucleotides can be removed from the 3 end LTR without affecting the efficiency of vector transduction. SFV-1 vector
can therefore accommodate a minimum 8930 base-size heterologous DNA fragment. Furthermore, the efficiency of SFV-1
vector transduction was analyzed using different packaging plasmids. GFP transduction with packaging plasmid that
contained the 5 R-U5 region of the LTR was compared with helper plasmids that had deletions in this region except for 22
nucleotides (positions 21–41), the first 61, 77, or 140 nucleotides of the R of the LTR. Transduction efficiencies wereINTRODUCTION
The development of retroviral vectors for gene transfer
into a variety of cells has contributed a major advance-
ment toward human gene therapy. Several of the gene
therapy studies using retroviral vectors are based on the
murine leukemia virus (MuLV) (Anderson, 1998; Gunji et
al., 2000; Morgan and Blaese, 1999; Mountain, 2000).
MuLV does not replicate efficiently in nondividing cells
and vectors based on MuLV appear to be inefficient in
vivo (Culver et al., 1990, 1991; Morgan et al., 1994; Naldini
et al., 1996; Woffendin et al., 1994). Lentiviruses such as
the human immunodeficiency virus (HIV) infect terminally
differentiated cells such as macrophages. Vectors based
on lentiviruses are, therefore, promising since they can
infect both dividing and nondividing cells (Akkina et al.,
1996; Naldini et al., 1996). Concern with the potential risk
associated with HIV, however, may hamper the usage of
these vectors in human gene therapy. Similarly, the re-
cent report that FIV can infect cynomolgus macaques
(Macaca fasicularis) with clinical signs, including deple-
tion of CD4 cells and weight loss, that are consistent
with FIV infection indicate the risk associated with the
usage of animal lentivirus-based vectors for human gene
therapy (Johnston et al., 2001). Foamy viruses offer the
opportunity to develop an alternative efficient and safe© 2002 Elsevier Science (USA)
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236vector system for gene therapy. These viruses are non-
pathogenic and infect a variety of cell types of different
species. More importantly, we previously established
that SFV-1 vectors transduce nondividing cells efficiently
implicating that quiescent nondividing cells such as hu-
man stem cells are prone to SFV-1-mediated gene trans-
fer (Mergia et al., 2001). Others, however, implicated that
cell cycling is required for foamy virus infection (Bieniasz
et al., 1995). Using foamy virus vectors encoding reporter
genes, it has been shown that foamy virus vectors can
transduce primitive murine hematopoietic cell progeni-
tors that engraft NOD/SCID mice and differentiate into
many hematopoietic lineages in vivo (Vassilopoulos et
al., 2001).
Several versions of foamy virus vectors based on sim-
ian foamy virus type 1 (SFV-1) and human foamy virus
(HFV) capable of gene transfer are available (Mergia and
Wu, 1998; Russell and Miller, 1996; Schmidt and Reth-
wilm, 1995; Wu et al., 1998; Wu and Mergia, 1999). Similar
to other retroviral vectors, these vectors contain the 5
untranslated leader region and the 5 end of the gag
gene which contains important cis-acting elements. The
5 untranslated region of foamy virus is highly conserved
among different strains and the sequence predicts fea-
tures of a secondary structure that is complex (Mergia
and Luciw, 1991; Mergia et al., 1992; Renne et al., 1993).
For other retroviruses, this region is required for viral
genome packaging, diploid genome dimerization, andsignificantly reduced with the deletion mutations implic
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sequence for foamy viruses is yet to be determined. The
sequence that is responsible for foamy virus genome
diploid dimerization is located between the primer-bind-
ing site and the gag gene (Erlwein et al., 1997; Heinkelein
et al., 2000; Russell et al., 2001). The R-U5 region is
implicated for efficient Gag and Pol translation (Heinke-
lein et al., 2000; Russell et al., 2001). Studies on foamy
virus vector construction suggest that additional se-
quences required for foamy virus vector transfer are
found in the 3 end of the pol gene (Erlwein et al., 1998;
Heinkelein et al., 1998; Wu et al., 1998). The role of these
sequences in foamy virus replication and vector con-
struction remains to be determined.
The transactivator (tas) gene of foamy virus is essen-
tial for virus replication (reviewed in Rethwilm, 1995).
Foamy virus vectors that are replication defective can
easily be constructed by deleting the tas gene and plac-
ing the genomes of the vector and the helper under the
control of a heterologous promoter (Park and Mergia,
2001; Trobridge and Russel, 1998). Although foamy virus
vector development has this advantage, a system with
minimal genome has yet to be established for versatile
gene therapy applications. This is mainly in part due to
the fact that the molecular mechanisms of foamy virus
replication is still in the process of being unraveled.
Based on strategies of other retroviral vector systems,
we have previously established packaging cell lines for
SFV-1 vector in which the construct is devoid of the R-U5
and the region between the LTR and the gag gene (Wu
and Mergia, 1999). With these cell lines we were able to
package SFV-1 vector genome and transduce cells sub-
sequently. The SFV-1 vector used to test the cell lines
contained a sequence from the 5 end of the genome to
the end of pol. It was not determined, however, whether
the gag gene was expressed from the vector and/or from
the packaging constructs used to establish the cell lines.
The recent findings that the R-U5 region of foamy virus is
required for efficient gag and pol gene expressions has
an implication in strategies for developing packaging cell
lines for foamy virus vectors (Heinkelein et al., 2000;
Russell et al., 2001). Unlike other retroviruses, therefore,
a packaging plasmid for the foamy virus vector system
may require sequences located in the R-U5 region for
efficient expression of the gag and pol. In lieu of this
information, here we report the minimum genome re-
quired for a SFV-1 vector system with efficient gene
transfer.
RESULTS
The effect of deletions in the gag and pol region on
SFV-1 vector transfer
To define the minimum genome required for gene
transfer with SFV-1 vector, we have introduced a series
of deletion mutants in the gag-pol regions as detailed in
Fig. 1. The efficiency of transduction of these vectors was
tested with the packaging plasmid pCRU5GPE, which
contained the R-U5 region, including the sequence be-
tween the LTR and the gag gene and structural genes
(Fig. 2). Previously it was demonstrated that the 5 un-
translated region including the 5 end of the gag gene
and the 3 end of pol to be critical for SFV-1 vector
construction (Wu et al., 1998). However, removal of se-
quences between these two regions (nucleotide posi-
tions 683-5190) completely affected gene delivery. The
previous experiments to determine the cis-acting ele-
ment required for vector analysis for SFV-1 vector were
performed with provirus as a helper plasmid and vector
expression was under the control of its own U3 promoter
and not the CMV promoter, which yielded low vector
titers (102-104 vector particles/ml). Efficiency of transduc-
tion with vector which contained the gag-pol region (pC-
CGL) with packaging plasmid pCRU5GPE was 4  106
vector particles/ml (Fig. 2). With our high titer vector
production system removal of the gag-pol region from
nucleotide positions 683 to 5200 (CCGL 493) resulted in
transduction efficiency of 4  104 vector particles/ml,
100-fold lower than the pCCGL vector. To enhance trans-
duction efficiency, the region from nucleotide position
684-1071 of gag was included in the vector (PvuII 493).
The inclusion of this sequence had no significant impact
on vector titer (7  104 particles/ml). Contrary to the
previous article (Wu et al., 1998), the addition of a stuffer
fragment into the CCGL 493 vector (PvuII 493/4kb) did not
affect transduction efficiency. The reason for these con-
tradictory results may be due to the usage of low-titer
vectors with the previous experiments. However, a five-
fold increase (2  105/ml) in GFP-positive cells was
observed when an additional 596 nucleotides of the pol
region from position 3137 to 3733 was included (dGP
493/596). Addition of more gag and/or pol sequences in
the dGP 493/596 vector as shown in Fig. 2 (dGP, dPol,
dGag, dGP/2kb, Hpa I960, dGP 608, and dGP493/596/
608) showed similar levels of vector transductions, giving
titers ranging from 2  105 to 8.4  105 vector particles/
ml. These results indicate that the minimal SFV-1 vector
which yields a significant level of vector production con-
tained the 5 end genome sequence which extends up to
the first 638 nucleotides of the gag gene, a 596 sequence
of pol at nucleotide position 3137–3733, and the 3 end of
pol at position 5200–5693, which was previously identi-
fied to be critical for vector construction.
To determine a maximum size of heterologous DNA
that can be accommodated in a foamy virus vector, we
further trimmed the vector by introducing a deletion in
the 3 LTR at nucleotide positions 10,299–11,227 (d2/804)
or at nucleotide positions 10,096–11,227 (d2 and d5)
using the backbone of dGP or dGP 493/596 (Fig. 1). In
these vectors we have also removed the sequence from
nucleotide position 9454 to 9956 of the orf-2 region
upstream of the polypurine tract (PPT). Both these vec-
tors gave similar levels of transduction efficiency when
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compared to the parental vector, indicating an additional
1596 nucleotide size DNA fragment can be removed from
SFV-1 vectors. Therefore, based on these observations
SFV-1 vector can accommodate a total of 8930 nucleo-
tide size heterologous DNA fragment.
Transduction efficiency with packaging plasmids in
the presence and absence of R-U5 of the 5 LTR
Previously we established packaging cell lines based
on a construct that lacks the 5 end noncoding region
except for a 22 nucleotide sequence at position 41–61 of
the R region, which contained the 5 end splice donor
site (pCGPET) (Wu and Mergia, 1999). The vector used
to test these cell lines for packaging had the 5 untrans-
lated and the entire gag-pol regions. To determine
whether pCGPET helps transduce genes as well as to
establish a basis for the SFV-1 vector system with a
minimal packaging plasmid, we examined the efficiency
of transduction using vectors that had deletions in gag-
pol. Each of the SFV-1 deletion vector constructs de-
picted in Fig. 1 was cotransfected with pCGPET. Vector
particles harvested were tested for efficiency of GFP
FIG. 1. SFV-1 vectors. Shown is the genome organization of the provirus SFV-1 and vector derivatives. Each of the vector genomes is under the
control of the human cytomegalovirus (CMV) immediate early gene promoter. Arrow indicates transcription start site. CMV-GFP is the coding
sequence of the GFP gene linked to the CMV immediate early promoter. The number represents sequence positions in the RNA genome of SFV-1.
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transduction (Fig. 3) and the results were compared
with transduction efficiency with packaging plasmid
pCRU5GPE (Fig. 2). There was either no GFP transduc-
tion or less than 10 vector particles/ml observed with
vectors CCGL 493, PvuII 493, PvuII 493/4kb, or dGP 493/
596 when the pCGPET packaging plasmid was used.
Vectors dGP, dPol, dGP  2kb, Hpa I960, and dGP 608
showed GFP transduction with titers 1.6  102-6  102
vector particles/ml. A slightly higher titer was observed
with vector dGag (3.8  103 vector particles/ml), indicat-
ing some gag-pol gene expression with pCGPET. The-
ses levels of gene transduction were significantly lower
compared to when the pCRU5GPE packaging plasmid
was used (Fig. 2). Vector CCGL, which has the entire
gag-pol, however, showed similar transduction efficiency
with both pCGPET and pCRU5GPE packaging plas-
mids, implying that the majority of Gag and Pol was
expressed from the CCGL vector.
To examine gag expression with the pCGPET pack-
aging construct, a radio-immunoprecipitation assay was
performed. Cell lysates transfected with each of the
packaging plasmids were radio-immunoprecipitated us-
ing polyclonal antibodies against Gag. As expected Gag
was expressed when the pCRU5GPE packaging plasmid
was transfected into 293T cells (Fig. 4). Both p74gag and
p70gag were detected in samples from cells transfected
with pCRUGPE construct. However, only p74gag was
present in samples from cells transfected with pCGPET
helper plasmid, even after 30 days exposure of the gel to
X-ray film. Although not quantitative, the level of p74gag
expression was lower with pCGPET when compared
with that of pCRU5GPE, reflecting the efficiency of vector
transduction observed in Figs. 2 and 3. In cells where the
pCGPET packaging plasmid was cotransfected with
CCGL vector, p74gag expression was increased and
p70gag was detected, indicating that the high level of
vector transduction is due to efficient expression of Gag
and Pol from the CCGL vector.
The role of R region of the LTR in SFV-1 vector
production
According to a recently published article, the first 130
nucleotides of the R region is required for gag and pol
FIG. 2. (A) Schematic representation of the packaging construct pCRU5GPE. 1 represents transcription initiation sites. Number at the 3end
represents SFV-1 sequence kept after deletion of the tas region. (B) Transduction efficiencies of SFV-1 vectors with pCRU5GPE helper plasmid. Vector
particles were produced by cotransfection of each of the vectors shown in Fig. 1 with pCRU5GPE. Viral supernatants were harvested 4 days
posttransfection and vector titers were determined by efficiency of GFP transduction. Titers were measured in triplicate from independent
transfections. A plasmid construct (CCGL) was used as a control to monitor for transfection efficiency.
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protein expression (Heinkelein et al., 2000; Russell et al.,
2001). To generate packaging plasmids with minimal
genome that expresses the structural genes, different
size fragments of DNA from the R region were cloned
between the CMV promoter and the gag gene (Fig. 5).
These constructs were tested for efficiency of GFP trans-
duction using SFV-1 vector which had a deletion in the
gag-pol region (dGP, Fig. 1). Inclusion of the first 61, 77, or
140 nucleotides of the R region between the CMV pro-
moter and the gag gene yielded 2.8  102, 5.5  102, or
3.8  104 vector particle/ml, respectively. These results
indicate the first 140 nucleotides of R are important for
SFV-1 vector production; however, the yield was10-fold
less compared to when pCRU5GPE packaging plasmid
was used. When CCGL vector was used, greater than 106
vector particles/ml were obtained with each of the pack-
aging plasmids. Since freeze-thaw of vector particles can
reduce titer, we compared these results with vector par-
ticles kept at 4°C to establish results that reflect the
actual effect of the different packaging plasmids. When
the packaging plasmid pCRU5GPE was used with the
vector dGP that had a gag-pol region deletion, the titer
was 10-fold higher (1.2  106 particles/ml) compared to
vector stocks kept at 80°C (1.7  105 particles/ml) (Fig.
5). Similarly with packaging plasmids containing different
size fragments from the R region, the vector particles
kept at 4°C had 10- to 100-fold higher titers than those
stocks from 80°C, implicating some level of gag and
pol gene expression with these constructs. Therefore,
titers of 3.6 105 vector particle/ml can be obtained with
the inclusion of 140 nucleotides between the CMV pro-
moter and the gag gene. This value is, however, at least
10-fold lower when compared with transduction effi-
ciency of the same vector with pCRU5GPE helper plas-
mid. Note that samples kept at 4°C from supernatants
FIG. 3. (A) Schematic representation of the packaging construct pCGPET. The construction of pCGPET is described elsewhere (Park and Mergia,
2001; Wu and Mergia, 1999). This helper construct contains 22 nucleotides of the SFV-1 of the R region which has the 5 end splice donor downstream
an intron. (B) Transduction efficiencies of SFV-1 vectors with pCGPET helper plasmid. Vector particles were produced by cotransfection of each of
the vectors shown in Fig. 1 with pCGPET. Titers were measured in triplicate from independent transfections. The expression cassette for hygromycin
with the thymidine kinase promoter and poly(A) addition signal is shown at the 3 end.
FIG. 4. Radioimmunoprecipitation assay with polyclonal antibodies
against Gag. The packaging plasmids pCRU5GPE (Lane 1) and
pCGPET (Lane 2), vector CCGL with pCGPET (Lane 3), or CCGL with
pCRU5GPE (Lane 4) were transfected into 293T cells. The cell lysates
from transfected cells metabolically labeled with [35S]methionine/lysine
overnight were immunoprecipitated with anti-gag serum and subjected
to 8% SDS–PAGE.
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harvested from cells transfected with CCGL along with
pCR5UGPE can give titers of 107 levels.
DISCUSSION
Foamy virus vectors have been implicated to be a
potentially ideal vector system for gene therapy. This
article investigates the minimal genome requirements for
SFV-1 vector system. A series of deletion mutations in
vector construction revealed that SFV-1 vectors with se-
quences that contain the 5 untranslated region extend-
ing to the first 637 nucleotides of the gag gene, the pol
region at nucleotide position 3137–3733, and the 3 pol
region at position 5200–5693 is a minimal genome vector
with relatively high transduction efficiency. Our deletion
analyses indicate that potentially a heterologous DNA
with a size of 8930 nucleotides long can be accommo-
dated in a SFV-1 vector. A significant reduction in vector
transduction was observed with a packaging plasmid
containing a 22 nucleotide sequence with the 5 end
splice donor of the R region. Vector transduction was
improved by including the first 140 nucleotides of the R
region in the packaging plasmid. However, transduction
was at least 10-fold lower compared to a packaging
plasmid that had the R-U5 region.
The R region of the HFV LTR was previously deter-
mined to be critical for expression of both Gag and Pol
proteins (Heinkelein et al., 2000; Russell et al., 2001).
Further study has mapped the essential sequence to the
first 130 nucleotides of the HFV for Gag and Pol expres-
sion (Russell et al., 2001). Analysis of Gag expression
with pCGPET revealed expression of the p74gag in-
stead of both p74gag and p70gag and the expression of
p74gag is reduced compared to when a packaging plas-
mid containing R-U5 (pCRU5GPE) was used. Heinkelein
et al. reported that when R-U5 was deleted, except the
first 65 nucleotides of R in HFV, no Gag and Pol expres-
sion was observed (Heinkelein et al., 2000). This HFV
construct used, however, lacked an intron between the
promoter and the 65 nucleotide. Russell et al. reported
the importance of an intron for Gag and Pol expression in
FIG. 5. (A) Transduction efficiency of packaging plasmids with deletions in the R region. Each packaging plasmid was cotransfected with vector
CCGL or dGP. Vector titer was determined after culture supernatant was stored either at 4°C or 80°C overnight. (B) Schematic representations of
the packaging constructs with different size R fragments placed between an intron downstream the CMV promoter and the gag gene. The numbers
indicate the nucleotide positions in the R region of SFV-1. The first 61, 77, or 140 nucleotide size of R was inserted between the intron and the gag
gene in the construct R1, R2, or R3, respectively.
241MINIMAL GENOME SIMIAN FOAMY VIRUS TYPE 1 VECTOR SYSTEM
the absence of the R-U5 region (Russell et al., 2001). Our
pCGPET construct, which we used to establish pack-
aging cell lines in a previous article (Wu and Mergia,
1999), has an intron 22 nucleotides upstream from R
explaining the expression of the p74gag. This 22 nucle-
otides of R also contains the 5 splice donor of SFV-1.
According to Heinkelein et al., the U5 region of HFV is
important for Gag processing and in the absence of U5
only p74gag was produced, confirming our finding with
pCGPET. Furthermore, SFV-1 vector transduction was
significantly reduced when pCGPET or R3 (which has
140 nucleotides of the R region with intron) packaging
plasmid was used. Our results demonstrated that for
optimum vector production more than the first 140 nucle-
otides of the R region are required even in the presence
of intron upstream of R.
The mechanism by which the R region exerts an effect
on translation is not known. Placing the R region of HFV
upstream a Cat gene had also shown the same effect on
expression of the reporter gene as it did on Gag (Russell
et al., 2001). Contrary to this observation, previous stud-
ies have shown the R-U5 region has an inhibitory effect
on the expression of Cat when placed between a pro-
moter and the gene (Mergia et al., 1992). From indepen-
dent studies, however, it is clear that R-U5 region influ-
ences gag-pol expression. Packaging constructs for
foamy virus vectors should, therefore, include the R-U5
region for optimum vector production. Since the tas gene
of foamy virus is critical for virus replication and vectors
without tas do not produce replication-competent virus,
the inclusion of the 5 untranslated region in the pack-
aging plasmid should not be a concern. The genome of
the helper can, however, potentially be packaged into a
virus particle influencing vector titer. The packaging sig-
nal sequence for foamy virus is not known. Our previous
study revealed that introduction of mutations in the re-
gion between the primer binding site and gag of SFV-1
had no effect on packaging (Park and Mergia, 2000).
Site-specific mutations in R and U5 that potentially dis-
rupt the predicted secondary structures in the 5 untrans-
lated region of SFV-1 did not affect packaging either.
Optimum SFV-1 vector productions as documented here
may, therefore, require a helper plasmid with the R-U5
region until a packaging signal sequence is identified.
Nevertheless, the results presented here demonstrated
efficient transductions with helper plasmid containing
the entire 5 untranslated region without generating rep-
lication-competent virus.
The fact that SFV-1 accommodates 8930 base size
DNA fragment with efficient gene transduction adds to
the advantages of foamy virus vector as an ideal tool for
gene therapy applications. The ideal gene transfer vector
will lack viral protein coding sequences and have a
capacity for a large transgene. A vector system that
serves as a delivery vehicle and allows expression of
several genes will be beneficial for gene therapy in
cases where more than one gene is required. SFV-1
vector can easily accommodate at least three to four
average size genes. Furthermore, foamy viruses are non-
pathogens and infect a variety of cells from different
species including nondividing cells. Therefore, the foamy
vector system may provide a safe and efficient means of




293T cells (human embryonic kidney fibroblasts con-
taining SV40 T antigen) were obtained from American
Type Culture Collection (Rockville, MD). Cells were
grown in Dulbecco’s modified Eagle’s medium supple-
mented with 10% fetal calf serum.
Plasmid constructions
All the SFV-1 vectors were constructed using pSP72 or
pSP73 plasmid (Promega, Madison, WI). Cloning proce-
dures were completed according to standard protocols
(Maniatis et al., 1989). pCCGL was generated by replac-
ing the LacZ gene with a GFP gene in the pCV7-9. The
construction of pCV7-9 was described previously (Wu
and Mergia, 1999). Deletions in the gag-pol region of
pCCGL were generated by taking advantage of the avail-
able restriction enzyme sites. CCGL 493 and PVUII 493
were generated by deleting sequences at positions 683-
5200 and 1071–5200 in the gag-pol, respectively. A 4.3kb
lambda HindIII fragment was inserted into CCGL 493 to
generate PvuII 493/4kb. Vector dGP was constructed by
introducing a deletion at position 1071–3137 in the gag
gene. In dGP/2kb the gag region at position 1071–3137
was replaced with 2.2-kb lambda HindIII fragment. In
Hpa I960 the sequences at position 1071–3733 of the
gag-pol region was removed. Sequences at positions
1071–2259 and 2555 to 3137 were deleted in CCGL to
generated dGag and dPol, respectively. The gag se-
quence at position 1651–2259 was included in dGag to
generate dGP 608. dGP 493/596 was created by insert-
ing the sequences from the pol region at positions 3137–
3733. Both sequences at positions 1651–2259 and 3137–
3733 were added into PvuII to construct dGP493/596/
608. To introduce mutations at the 3 LTR U3 regions dGP
493/596 vector was used. The sequence at position
10,299–11,227 was deleted to create d2/804. In d2 and d5
the region from nucleotide position 10,096 to 11,227 was
removed. An additional deletion was introduced in d2,
d2/804, and d5 at position 9454–9956.
The construction of the packaging plasmid pCGPET
is described previously (Park and Mergia, 2001; Wu and
Mergia, 1999). Packaging plasmid pCRU5GPE was con-
structed by placing a SFV-1 sequence that contains the
R-U5 and leader in between the CMV promoter and the
242 PARK, NADEAU, AND MERGIA
gag gene of plasmid pCGPET. Using the same strategy
the first 77, 120, and 140 nucleotides of the R were cloned
between the CMV promoter and the gag gene in
pCGPET to generate packaging plasmids R1, R2 and
R3, respectively.
Transfections and transductions
Transfections of 293T cells were carried out in six-well
plates by the liposome-mediated method with reagent
LipofectAmine according to manufacturer’s recommen-
dations (Life Technologies, Inc., Gaithersburg, MD). Each
of the SFV-1 vectors was transfected with a packaging
plasmid and vector particles were harvested as de-
scribed previously (Park and Mergia, 2001). Briefly, cells
were seeded at a density of 4 105 in six-well plates and
transfected with 1–2 g DNA. To enhance SFV-1 vector
production, cells were stimulated the next day with 10
mM sodium butyrate (Sigma) for 12 h and supernatant
was harvested at Day 3 to 4 posttransfection. Superna-
tants were stored at 80°C unless indicated. The
amounts of SFV-1 vectors produced were titered on fresh
293T cells plated at a density of 2.5  104 in 24-well
plates. A plasmid construct (CCGL) was used as a con-
trol to monitor for transfection efficiency.
Radio-immunoprecipitation assay
Cells transfected with each of the packaging plasmids
were metabolically labeled for 16 h with [35S]Met/Cys
(Amersham Pharmacia Biotech, Piscataway, NJ) at a con-
centration of 100 mCi/ml. Labeled cells were washed
with ice-cold PBS and lysed with 1 RIPA (20 mM Tris
pH 7.4, 0.3 M NaCl, 1% Triton X-100, 1% sodium deoxy-
cholate, 0.1% SDS, 0.02% sodium azide, 0.1% gelatin, 1
mM PMSF) buffer. Cell lysates were clarified by high-
speed centrifugation and 300 l lysate was reacted with
5 l rabbit anti-gag SFV-1 serum (kindly provided by Dr.
Axel Rethwilm of Institut fuer Virologie im MTZ, Dresden,
Germany) in a 500 l volume. After incubation with pro-
tein A-Gel (Bio-Rad) and an extensive wash with 1
RIPA, the complex was disrupted by boiling for 2 min and
analyzed by SDS–PAGE. The gel was fixed, soaked in
fluorographic reagent (Amplify, Amersham), dried, and
then exposed to X-ray films (Kodak) for 3 days at 70°C.
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